Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.17 +1.71%

+$0.29 today

Market cap
$1.52B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 2.07M

Average 3.08M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$205.48M

FY 2025 · Annual

Investing Cash Flow

$69.64M

FY 2025 · Annual

-90.8% YoY

Financing Cash Flow

-$168.34M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(418.78M)(703.49M)(535.98M)235.24M(713.41M)
Depreciation & Amortization38.02M41.86M44.4M37.72M44.52M
Deferred Income Tax15.81M0000
Stock-Based Compensation113.94M233.02M182.51M184.3M123.4M
Change in Working Capital(98.17M)(39.47M)(481.09M)(716.61M)78.04M
Accounts Receivables(51.65M)(61.64M)(185.7M)(201.66M)203.76M
Inventory(83.77M)(50.78M)(147.71M)(395.17M)(301.09M)
Accounts Payables23.3M147.57M(50.14M)110.65M104.27M
Other Working Capital13.96M(74.62M)(97.54M)(230.42M)71.11M
Other Non-Cash Items(94M)142.73M289.16M53.56M261.98M
Operating Cash Flow(443.17M)(325.35M)(500.99M)(205.79M)(205.48M)
Capital Expenditures(38.49M)(32.25M)(87.35M)(146.96M)(101.97M)
Acquisitions (Net)00000
Purchases of Investments(29.99M)(1.94B)(2.05B)(1.1B)(44.66M)
Sales of Investments466M923.22M1.87B2B469.97M
Other Investing Activities97.89M(1.43M)90.76M(10M)(253.7M)
Investing Cash Flow495.41M(1.05B)(165.8M)755.56M69.64M
Debt Repayment0304.17M0(68K)(162.59M)
Common Stock Issued548.53M00036.32M
Common Stock Repurchased0000(25.01M)
Dividends Paid00000
Other Financing Activities13.04M(71.66M)125M124.87M(17.06M)
Financing Cash Flow561.57M232.51M125M124.81M(168.34M)
Effect of Forex Changes00000
Net Change in Cash613.81M(1.14B)(541.79M)674.58M(304.18M)
Free Cash Flow(481.66M)(357.6M)(588.34M)(352.74M)(307.45M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$713.4M
+ D&A$44.5M
+ Stock-Based Comp$123.4M
+ Deferred Tax$0
+ Working Capital$78.0M
+ Other Non-Cash$262.0M
= Operating Cash Flow-$205.5M
- Capex-$102.0M
= Free Cash Flow-$307.5M

Analysis

FY2025 free cash flow is -$307.5M. FCF conversion is 43.1% of net income. Operating cash flow was -$205.5M, with capex of -$102.0M. The largest bridge item is Other Non-Cash at $262.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
13F-HR13F-HR filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026

Does SRPT generate free cash flow?

Sarepta Therapeutics, Inc. (SRPT) generated -$307.45M of free cash flow in fiscal 2025.

How much operating cash flow does SRPT produce?

Operating cash flow was -$205.48M, before capital expenditures of $101.97M.